Axonics Valuation
Is AXNX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AXNX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AXNX * (MX$861.54) is trading below our estimate of fair value (MX$1169.46)
Significantly Below Fair Value: AXNX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AXNX *?
Other financial metrics that can be useful for relative valuation.
What is AXNX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.94b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8.2x |
Enterprise Value/EBITDA | -428.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AXNX *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7x | ||
NARI Inari Medical | 5.6x | 15.6% | US$2.8b |
INSP Inspire Medical Systems | 7.1x | 17.4% | US$4.6b |
688301 iRay Technology | 9.9x | 21.0% | CN¥19.0b |
IRTC iRhythm Technologies | 5.4x | 14.3% | US$2.7b |
AXNX * Axonics | 9.2x | 17.8% | Mex$2.9b |
Price-To-Sales vs Peers: AXNX * is good value based on its Price-To-Sales Ratio (9.2x) compared to the peer average (11.1x).
Price to Earnings Ratio vs Industry
How does AXNX *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Sales vs Industry: AXNX * is expensive based on its Price-To-Sales Ratio (9.2x) compared to the Global Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is AXNX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AXNX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.